View Older Stories View More Recent Stories

Jun 3, 2017 07:43AM Abiraterone Acetate Provided Significant Clinical Benefit in Patients with High-Risk Metastatic Hormone-Naïve Prostate Cancer (mHNPC), Improving Overall Survival and Radiographic Progression-Free Sur
May 17, 2017 05:47PM Janssen (JNJ) to Present 19 Abstracts at ASCO
May 17, 2017 05:44PM ASCO 2017: Janssen to Present 19 Abstracts in Prostate Cancer and a Spectrum of Blood Cancers; Includes Data on Abiraterone Acetate, Daratumumab and Ibrutinib
May 17, 2017 06:44AM Johnson & Johnson Showcases Strong Pipeline of Transformational Medicines at its Pharmaceutical Business Review Meeting
Apr 4, 2017 07:05AM U.S. FDA Accepts for Review the Application of Ibrutinib (IMBRUVICA®) for Chronic Graft-Versus-Host-Disease (cGVHD) After Failure of One or More Lines of Systemic Therapy
Mar 31, 2017 05:41AM Johnson & Johnson (JNJ) Declares $30B Actelion Tender Successful; Controls 77.% of Voting Rights
Mar 31, 2017 01:01AM Johnson & Johnson publishes interim result for Actelion tender offer and declares the tender offer successful
Mar 31, 2017 01:00AM Johnson & Johnson Publishes Interim Result for Actelion Tender Offer and Declares the Tender Offer Successful
Mar 23, 2017 10:09PM YouTube's bid to grab TV dollars imperiled by advertiser revolt
Mar 23, 2017 09:00AM Ethicon Announces Completion Of Acquisition Of Torax Medical, Inc.
Mar 15, 2017 03:30PM With Over 42,000 Votes In 25 Categories BabyCenter's 2017 Moms' Picks Showcase Parents' Favorite Products
Mar 8, 2017 06:12AM 'It's like kumbaya': Trump's genial private meetings with CEOs jar with public attacks
Mar 3, 2017 07:08AM Janssen (JNJ) Says Second Phase 3 Study Shows Significant Efficacy of Guselkumab And Superiority Versus Humira in Treatment Plaque Psoriasis
Mar 3, 2017 07:00AM New Results From Second Phase 3 Study Show Significant Efficacy Of Guselkumab And Superiority Versus Humira® In Treatment Of Moderate To Severe Plaque Psoriasis
Feb 17, 2017 10:00AM Ethicon Announces Agreement to Acquire Torax Medical, Inc.
Feb 17, 2017 08:00AM New Data Shows STELARA® (ustekinumab) Maintained Clinical Response And Remission After Two Years Of Treatment In Adult Patients With Moderately To Severely Active Crohn's Disease
Feb 16, 2017 01:00AM Johnson & Johnson Publishes Prospectus For Actelion Tender Offer
Feb 2, 2017 08:00AM Janssen Human Microbiome Institute Announces Multiple Collaborations to Accelerate the Translation of Microbiome Science into Health Solutions
Jan 26, 2017 05:45AM Johnson & Johnson (JNJ) to Acquire Actelion (ALIOY) For $30B; to Spin-Off New R&D Company
Jan 26, 2017 01:18AM Johnson & Johnson To Acquire Actelion For $30 Billion With Spin-Out Of New R&D Company
Jan 23, 2017 08:30AM The ECHELON FLEX™ GST System Will Now Feature A 45mm Endocutter With Exclusive Gripping Surface Technology Reloads
Jan 20, 2017 08:35AM Ethicon Announces Acquisition of Megadyne Medical Products (JNJ)
Jan 20, 2017 08:30AM Ethicon Announces Acquisition of Megadyne Medical Products, Inc.
Jan 19, 2017 07:05AM IMBRUVICA® (ibrutinib) Approved by FDA for Marginal Zone Lymphoma (MZL) Patients Who Require Systemic Therapy and Have Received At Least One Prior Anti-CD20-Based Therapy
Jan 5, 2017 07:05AM Bristol-Myers Squibb (BMY) Enters Collaboration with JNJ's (JNJ) Janssen for Opdivo/Darzalex Combo
Jan 5, 2017 06:59AM Janssen Enters Immunotherapy Clinical Collaboration with Bristol-Myers Squibb to Evaluate daratumumab (DARZALEX®) in Combination with nivolumab (OPDIVO®)
Jan 4, 2017 10:00AM 71% Of Today's Parents Own At Least One 'Internet Of Things' Device & Three-Quarters Of Those Without IoT Are Interested And Want To Learn More, According To BabyCenter Research
Dec 20, 2016 04:48PM Johnson & Johnson's (JNJ) Janssen Submits Two Applications to FDA for SIMPONI ARIA
Dec 20, 2016 04:45PM Janssen Submits Two Applications To FDA Seeking Approval Of SIMPONI ARIA® (golimumab) For The Treatment Of Active Psoriatic Arthritis And Active Ankylosing Spondylitis
Dec 16, 2016 07:48AM Johnson & Johnson's (JNJ) Janssen Submits STELARA sBLA to FDA for the Treatment of Adolescents with Plaque Psoriasis
Dec 16, 2016 07:45AM Janssen Submits Application Seeking FDA Approval of STELARA® (Ustekinumab) for the Treatment of Adolescents with Moderate to Severe Plaque Psoriasis
Dec 6, 2016 10:37AM AbbVie (ABBV) Announces Presentation of Positive IMBRUVICA Phase 2 Data in cGVHD
Dec 6, 2016 10:36AM Janssen Announces Encouraging Data from IMBRUVICA Phase 2 in cGVHD
Dec 6, 2016 10:35AM Late-breaking Phase 2 Ibrutinib Study in Chronic Graft-Versus-Host-Disease (cGVHD) Showed Complete or Partial Response in Up to Two-Thirds of Steroid Dependent or Refractory Patients
Dec 6, 2016 08:00AM New Analysis Shows People with Cancer Who Received XARELTO® (rivaroxaban) for Blood Clots Had Fewer ER Visits and Lower Healthcare Costs than Those Given Standard Treatment
Dec 6, 2016 06:36AM Janssen Announces Strong ORR Data from IMBRUVICA Phase 2 in r/r MZL
Dec 6, 2016 06:17AM Janssen Announces Significant Data from Two DARZALEX Phase 3 Post-Hoc Analyses
Dec 5, 2016 09:20PM New Ibrutinib (IMBRUVICA®) Phase 2 Data Demonstrate Promise in Relapsed/Refractory Marginal Zone Lymphoma (MZL), a Rare, Incurable Type of Non-Hodgkin's Lymphoma
Dec 5, 2016 07:30PM Daratumumab (DARZALEX®) Combination Therapy Showed Consistent Clinical Benefit for Previously-Treated Patients with Multiple Myeloma
Dec 5, 2016 06:26AM Janssen Announces Follow-up Data on IMBRUVICA Phase 1b/2 as CLL/SLL Treatment (JNJ)
Dec 3, 2016 07:05PM Data at ASH 2016 Show Strong, Lasting Efficacy of IMBRUVICA® (ibrutinib) Through Five Years of Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Nov 30, 2016 02:17PM BabyCenter® Reveals Top Baby Names Of 2016
Nov 21, 2016 04:39PM Janssen's DARZALEX Combo Approved by U.S. FDA as Multiple Myeloma Treatment (JNJ)
Nov 21, 2016 04:37PM DARZALEX® (daratumumab) Approved by U.S. FDA in Combination with Two Standard of Care Regimens for the Treatment of Patients with Multiple Myeloma Who Have Received At Least One Prior Therapy
Nov 17, 2016 08:18AM Janssen Submits BLA to FDA Seeking Approval of Guselkumab for Treatment of Severe Plaque Psoriasis (JNJ)
Nov 17, 2016 08:00AM Janssen Submits Application To FDA Seeking Approval Of Anti-Interleukin-23 Monoclonal Antibody Guselkumab For The Treatment Of Moderate To Severe Plaque Psoriasis
Nov 16, 2016 11:02AM Janssen Announces Significant Data from Two SC Sirukumab Phase 3s as RA Treatment
Nov 16, 2016 11:00AM New Phase 3 Monotherapy Study of Sirukumab Versus Humira® and Sirukumab Data in an Anti-TNF Refractory Population Reported in the Treatment of Moderately to Severely Active Rheumatoid Arthritis
Nov 15, 2016 08:00AM Janssen Next-Generation Biologic Guselkumab Shows Promise In The Treatment Of Psoriatic Arthritis In Phase 2 Trial
Nov 14, 2016 11:46AM Janssen Announces XARELTO Phase 3b Met Primary Endpoint in NVAF Patients
View More Recent Stories View Older Stories